Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCS-01 Eye Drops in Diabetic Macular Edema
2023-507207-66-00Phase 3Completed
- Sponsor
- Oculis
- Start
- May 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of OCS-01 in diabetic macular edema (DME), sponsored by Oculis. Primary endpoint: Mean change in BCVA ETDRS letters at Week 52. Started May 2024; status: completed.
02
Drugs
OCS-01
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2023-507207-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507207-66-00.